

La Renon

A Synergistic Solution for
HYPERLIPIDEMIA



IMPUROSE-EZ 10

Rosuvastatin 10 mg + Ezetimibe 10 mg Tablets

IMPUROSE-EZ 20

Rosuvastatin 20 mg + Ezetimibe 10 mg Tablets

IMPUROSE-EZ 10,20

Rosuvastatin 10/20 mg + Ezetimibe 10 mg Tablets

Background:

Statins have been the gold standard therapy for hypercholesterolemia treatment but unfortunately, statin therapy alone is not always effective enough to adequately control a patient's elevated lipid levels and combination therapy may be warranted. Adding ezetimibe to a statin has been shown to enable higher proportions of patients to attain guideline recommended cholesterol levels and allows for the use of lower statin dosages, which may be of particular benefit in patients prone to the dose-dependent adverse effects of statins. A standard dose of 10 mg/day ezetimibe reduces LDL-C by 15–20% when used as monotherapy and in combination with statin has shown to have a greater effect. In this regard, rosuvastatin and ezetimibe combination therapy seems to be a good option when the maximum tolerable dose of statin cannot sufficiently reduce LDL-C.

Description:

IMPUROSE-EZ is the combination of Rosuvastatin and Ezetimibe two lipid-lowering agents: Rosuvastatin, an HMG-CoA reductase inhibitor and Ezetimibe, a dietary cholesterol absorption inhibitor.

IMPUROSE-EZ 10 : Rosuvastatin 10 mg + Ezetimibe 10 mg Tablets

IMPUROSE-EZ 20 : Rosuvastatin 20 mg + Ezetimibe 10 mg Tablets

Indication:

IMPUROSE-EZ 10/20 is indicated as an adjunct to diet in patients with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C).

Mechanism of Action:

Rosuvastatin: Rosuvastatin competitively inhibits HMG-CoA reductase enzyme selectively and reversibly. This enzyme converts HMG-CoA to mevalonic acid in the cholesterol biosynthesis pathway which is the rate limiting step in cholesterol synthesis.

Ezetimibe: The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood.

Dosage:

- The recommended dosage of **IMPUROSE-EZ 10,20** is One Tablet a day orally.
- In patients with severe renal impairment, not on hemodialysis, the dosage should not exceed Rosuvastatin 10 mg and Ezetimibe 10 mg once daily orally.
- There are no dosage adjustment recommendations for patients with mild and moderate renal impairment.

References:

1. J Thorac Dis. 2017 May;9(5):1226-1233
2. Clin Ther. 2017 Jan;39(1):107-117

La Renon Healthcare Private Limited

207-208 Iscon Elegance | Circle P | Prahlad Nagar Cross Roads
S.G. Highway, Ahmedabad-380015 | Gujarat, India.
Phone: + 91-79-6616-8998 / 2693-6656 | Fax: +91-79-6616-8998
E-mail: info@larenon.com | Web: www.larenon.com

© All Rights Reserved, La Renon Healthcare Private Limited.

Scan for more
Prescribing Information



I am: _____
Call me on: _____
Mail me at: _____